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Abstract
Background: Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disorder that if left untreated
can result in bone destruction and severe continuing pain due to persistent inflammation. The impact this chronic
disease has on the daily lives of affected children and their families is not well known. The purpose of this study is
to understand the disease burden and socioeconomic and psychological impact of CNO from the patients’ and
families’ perspectives and identify areas of improvement for patient care and reduced disease burden based on
patients’ and families’ responses.
Methods: Participants were invited through a social media platform group and at clinic visits at Stanford Children’s
Health. An online survey was administered to patients with a diagnosis of CNO made at < 22 years of age and/or
the parent/guardian of a patient with CNO diagnosis made at < 22 years of age.
Results: There was a total of 284 survey participants. The median age at CNO diagnosis was 10 years (range 2–22+).
Median time from first CNO symptom to diagnosis was 2 years. Antibiotics were used in 35% of patients prior to
CNO diagnosis; of these, 24% received antibiotics for greater than 6 months. Between 25 and 61% reported a
negative effect of CNO on relationships, school/work performance, or finances; and 19–50% reported effects on
psychosocial well-being. The majority agreed patients’ performance with daily tasks and hobbies was challenged
by pain, fatigue and physical limitation related to CNO.
Conclusions: Patients with CNO experienced on average a 2-year delay in diagnosis and receiving effective
treatments. At least 25% reported problems with relationships, school, work, finances and well-being due to CNO.
Recognition of these challenges emphasizes the need to increase awareness of this disease and address the
socioeconomic stressors and mental health issues in order to provide optimal care of children with CNO.
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Background
Chronic recurrent multifocal osteomyelitis (CRMO), or
the broader term chronic nonbacterial osteomyelitis
(CNO), is an autoinflammatory bone disorder that typic-
ally presents as an insidious onset of bone pain with or
without localized swelling, warmth and tenderness. CNO
can be unifocal or multifocal at onset but the majority of
children with a unifocal lesion at onset have multifocal
lesions within 4 years, [1]. It commonly affects the long
bones, pelvic bone, vertebrae and clavicle; however, almost
any bone may be involved, so symptoms may vary, [2, 3]. If
left untreated, persistent inflammation can result in bone
destruction, severe continuing pain, growth disturbances,
functional limitation and pathological fractures, [4–7].
There is no confirmatory diagnostic test for CNO. It is
diagnosed by excluding other bone and inflammatory dis-
eases. Due to the gradual onset, minimal physical exam
findings and low sensitivity of radiographs, children with
CNO may experience delays in diagnosis and access to a
pediatric rheumatologist and ineffective treatments such
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as prolonged courses of antibiotics [2, 8–10]. Once a diag-
nosis of CNO is made, first line management is often non-
steroidal anti-inflammatory drugs (NSAIDs), [11, 12].
However, children with severe CNO or a recurrent multi-
focal course have higher rates of complications, such as
pathological fractures and hyperostosis, and may require
more aggressive treatment such as bisphosphonate and/or
tumor necrosis factor (TNFi) inhibitors, [1, 7].
The impact this chronic disease has on the daily lives
of affected children and their families may be substantial.
Most studies involving children with CNO evaluated the
long-term clinical outcomes from a management or dis-
ease activity perspective, [1–3, 7, 10, 13, 14]. While these
studies address important concerns regarding the clinical
outcomes of children with CNO, only a few have add-
itionally addressed quality of life and psychosocial issues.
In one inception cohort of 23 patients with CRMO, Hu-
ber et al. found that many patients had impairments in
all domains of the quality-of-life testing, [2].
Catalano-Pons et al. evaluated educational and voca-
tional achievements in a cohort of 40 patients with CNO
and reported that a majority considered CRMO to have
some global repercussion on their life and two patients
reported CNO had interfered with their education, [13].
Silier et al. was the first study to highlight the difficulties
of CNO from the patient perspective. In this cohort,
many patients reported CNO affected their school and
job attendance and had a negative influence on their
family, friends, and work, [10]. However, more studies
are needed to address the disease burden and the unmet
need of psychosocial support for this chronic disease.
The purpose of our study was to understand the socio-
economic and psychological impact of CNO from the
patients’ and families’ perspectives, with the goal of iden-
tifying areas of improvement for patient care and re-
duced disease burden. We surveyed patients and their
families about the difficulties they encountered with the
diagnosis and management of CNO and the impact on
their quality of lives.
Methods
An online survey was designed in REDCap, which is a se-
cure, web-based application designed to support data cap-
ture for research studies, [15]. The survey consisted of 100
questions centered around three aspects: pre-CNO diagno-
sis management, CNO disease management and quality of
life. Questions focused on epidemiological information, ini-
tial clinical presentation, physician(s) seen prior to CNO
diagnosis, management before and after CNO diagnosis,
diet, function and performance of daily tasks, school and
work attendance, finances, peer and family relationships, fa-
tigue, anxiety, depression, anger and sleep problems. Race
and ethnicity were asked separately and were self-reported.
The survey questions were developed by the study team
and reviewed and refined by the parents of patients with
CNO and the Childhood Arthritis and Rheumatology Re-
search Alliance (CARRA) CRMO/CNO workgroup.
This study was approved by Stanford University Insti-
tutional Review Board (IRB Protocol # 36393) before
distribution. The inclusion criteria for the survey study
was patients with a diagnosis of CNO made at < 22 years
of age and/or the parent or guardian of a patient with a
diagnosis of CNO made at < 22 years of age. Exclusion
criteria was not having a diagnosis of CNO or a parent
or guardian not having a child with CNO.
Participants were recruited in two ways: 1) at their Stan-
ford Children’s Health clinic visits, and 2) through the Face-
book CRMO support group page. The Facebook group
(http://www.facebook.com/groups/CRMOawareness) titled
“CRMO: Chronic recurrent multifocal osteomyelitis” is an
international group for patients and families dealing with
CRMO. Interested participants received information re-
garding the study and the link to the online survey either at
their clinic visits with their primary rheumatologist or
through the Facebook CRMO support group webpage. The
principal investigator partnered with the parent liaisons of
the CARRA CRMO/CNO workgroup and the Facebook
page to send reminders each month. The online survey link
was available for 3months from August 1st to October
31st, 2016. The survey was voluntary and anonymous. In-
formed consent was obtained online immediately prior to
initiating the survey.
Descriptive statistics were performed to report the re-
sults of the survey. Results were expressed as median
(ranges) for continuous variables and as frequencies
(percentages) for categorical variables. Study data were
collected and managed using REDCap hosted at the
Stanford Center for Clinical Informatics. Statistical ana-
lysis was performed on SAS software v9.4.
Results
A total of 350 participants initiated the survey, however,
66 responses were excluded because they did not con-
sent (n = 61) or disease onset was after the age of 21
years (n = 5). A total of 284 survey responses were in-
cluded in the final analysis, though 75 only partially
completed the survey. The response rate was 26% based
on 1334 members in the Facebook CRMO support
group at the time of the study and 3 clinic patients.
Baseline characteristics and patient demographics are
presented in Table 1. The majority of survey responses
were completed by the parent or guardian (87%). Most
participants were from the United States (62%) followed
by: Europe (22%), Canada (7%), Australia (7%), Central/
South America (1%) and other (1%). The median age of
first CNO symptoms was 8 years (range 1-19y), and the
median age at CNO diagnosis was 10 years (range
2-21y). The median time from the first CNO symptom
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to diagnosis was 2 years, with 48% of participants first see-
ing a pediatric rheumatologist after having 12months of
symptoms. Others reported first seeing a pediatric rheuma-
tologist at 6–12months (20%) and less than 6months
(32%) after their first CNO symptom. The three most com-
mon physicians seen prior to the diagnosis of CNO were
primary care physicians, orthopedic surgeons, and infec-
tious disease specialists. The rheumatologist was the fourth
most common physician seen and a majority (67%) of pa-
tients were diagnosed with CNO by a pediatric rheumatolo-
gist. A bone biopsy was performed in 79% of patients for
the diagnosis of CNO. The most frequent comorbidity was
acne (n = 30, 11% of patient participants). Psoriasis was re-
ported in 10% of patients, followed by palmar-plantar pus-
tulosis (PPP; 8%) and juvenile idiopathic arthritis (6%).
Figure 1 displays the distribution of therapies used be-
fore and after a diagnosis of CNO. Prior to a diagnosis
of CNO, NSAIDs were the most common treatment
used (61%), followed by antibiotics (35%). Of those pa-
tients who were prescribed antibiotics, 24% received
them for greater than 6 months duration, 12% for 3–6
months and the remaining patients received antibiotics
for less than 3months. Additional management reported
prior to a diagnosis included surgery (16%) and radiation
therapy (n = 1). After a diagnosis of CNO, NSAIDs were
the first medication started in the majority of patients
and the most common treatment used (88%). There was
a marked increase in disease-modifying antirheumatic
drugs (DMARDs), TNFi, and bisphosphonates use after
a diagnosis of CNO was made compared to before.
Table 1 Baseline Characteristics and Patient Demographics (n = 284)
Characteristics n*
Median age of first CNO symptoms, year (range) 8 (1–19)
Median age of CNO diagnosis, year (range) 10 (2–22+)
Survey completed by parent (%) 87 246
Male (%) 34 246
Race, white/Caucasian (%) 92 245





Time from symptom onset and 1st pediatric rheumatologist visit (%) 239
< 6 mo 32
6–12 mo 20
> 12 mo 48




Biopsy performed (%) 79 213
Received antibiotics prior to CNO diagnosis (%) 35 284
Treated with antibiotics > 6 mo 24 96





JIA (excluding ERA) 6
AS/ERA 3
Uveitis 3
PCP = primary care physician; IBD = inflammatory bowel disease; AS/ERA = Ankylosing Spondylitis/Enthesitis related arthritis; JIA = juvenile idiopathic
arthritis; PPP = Palmoplantar pustulosis; mo = month
*= number of participants who responded to survey question
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There were still 7% of patients who reported using anti-
biotics after the diagnosis of CNO.
Participants were asked which medication from a list
of 21 choices they found to be the most helpful for the
treatment of their CNO. Medications categories included
steroids, antibiotics, NSAIDs, DMARDs, biologics, pre-
scription pain medications, none and other. As shown in
Table 2, in patients who also took NSAIDs at some point
during their treatment, TNFi and bisphosphonate were
considered to be the most helpful in 44 and 37% of par-
ticipants, respectively, whereas DMARDs were consid-
ered most helpful in only 10%. It is important to note
that of these patients, 65, 71 and 77% of patients were
not exposed to DMARDs, TNFi or bisphosphonate, re-
spectively. Among all the participants who took
NSAIDs, 30% reported that NSAIDs were most helpful.
Other medications were reported in lower numbers
(prescription pain medications n = 5, colchicine n = 2,
antibiotics n = 0 and other biologics n = 0 (i.e., IL-1 or
IL-6 inhibitors)). Lastly, 27 (13%) reported that none of
the medications were helpful. Those who reported that
none of the medications were helpful also had prior use
of NSAIDs (74%), DMARDs (30%), prescription pain
medication (30%), TNFi (22%), bisphosphonates (22%),
corticosteroids (19%) and antibiotics (15%).
Other non-medicine therapeutics were commonly im-
plemented in children with CNO. A majority (51%) re-
ported doing physical therapy (PT) or occupational
therapy (OT) for CNO-related needs. However, of those
who participated in PT or OT, only 30% found it to be
helpful, while 32% reported it as somewhat helpful and
38% as not helpful. Open-ended responses for why PT
or OT was only partially or not helpful were: it caused
more pain, there was no improvement in the pain and
the physical therapist did not understand the disease.
Dietary modifications for the management of CNO was
also tried (35%), with gluten-free being the most com-
mon diet.
Imaging was frequently performed for the management
of CNO. Almost all patients had an X-ray (91%). A CT
Fig. 1 Treatments Prescribed Before and After CNO Diagnosis. Number of participants who responded to survey question for before diagnosis (n= 251)
and after diagnosis (n = 248). NSAID: nonsteroidal anti-inflammatory drugs. DMARD: disease modifying anti rheumatic drug. TNFi: tumor
necrosis factor inhibitor. *Surgery and radiation were not asked about after CNO diagnosis





as most helpful*, n
% (95% CI)
TNFi 81 36 44% (33–56%)
Bisphosphonate 65 24 37% (25–50%)
NSAID 217 65 30% (24–37%)
Corticosteroids 101 17 17% (10–26%)
DMARD 100 10 10% (5–18%)
*Question formatted: “Which of the following medications has been most helpful for your CRMO/CNO?”. Total responses = 216
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scan was performed in 55% of patients and a bone scan in
62%. MRI was performed in 88% and whole-body MRI
(wbMRI) was done for 57% of patients. However, 26.7%
reported difficulty with obtaining MRI imaging. Common
reasons were the availability of MRI and insurance
denials.
A majority of patients (61%) reported CNO negatively
affected their participation in activities, and CNO af-
fected their school or work attendance (53%) as shown
in Table 3. Other areas that were negatively affected in-
cluded school performance (36%), parent’s job attend-
ance or performance (34%) and finances (36%). Only
36% of patients had formal school accommodations in
place, such as a 504 plan. The use of assisted devices at
some time during their disease course was reported by
42% of patients. Responses to the patient’s perception of
how CNO affects their physical function and perform-
ance are displayed in Fig. 2. The majority agreed that the
patients’ function and performance were challenged
by pain, fatigue and physical limitation related to CNO
and that they were unable to keep up with their peers.
Of those who agreed, a significant portion had strongly
agreed they were unable to perform their daily tasks due
to pain (41%), physical limitations (36%) and fatigue re-
lated to CNO (28%).
Additionally, in Table 3, fatigue was seen in half of the
patients with CNO. Between 25 and 30% reported a
negative effect on their relationships with their parents,
siblings and peers. A negative effect on the patient’s psy-
chosocial well-being was found, with 35, 32 and 19% of
participants self-reporting anxiety, depression and issues
with anger management, respectively.
Discussion
Our study demonstrates the significant burden that
CNO can have on the lives of patients and their families
from their perspectives. Overall, patients experienced a
median of a 2-year delay in diagnosis of CNO, which is
similar to previously reported studies, [1, 13]. The delay
may be due to a lack of awareness of CNO worldwide.
Most patients will see their primary care physicians,
orthopedic surgeons or infectious disease specialists
prior to seeing a pediatric rheumatologist. Targeting
these physicians with updated information on CNO
through collaboration with pediatric rheumatologists will
increase awareness and lead to earlier referrals, diagnosis
and quicker initiation of appropriate treatment. Roderick
et al. demonstrated that a letter sent to orthopedic sur-
geons led to an increase in referrals of patients with
CNO to pediatric rheumatology, [8]. CNO’s insidious
disease onset and the approach of diagnosis by exclusion
may also contribute to the delayed diagnosis. The rela-
tive timing of the first MRI from the first symptom was
not obtainable from our survey. Thus, it remains un-
known whether a delayed MRI may contribute to the de-
layed final diagnosis.
More than one quarter reported difficulties with
obtaining MRI imaging. MRI is superior to X-ray and
bone scintigraphy for identifying and monitoring active
CNO lesions, [16]. X-rays can be normal if done early in
the disease course. Bone scintigraphy is less sensitive for
determining active lesions in the metaphysis or epiphysis
of the long bones in growing children. Furthermore,
about 30% of patients with CNO may have asymptom-
atic lesions that are only detected by wbMRI, [8]. Having
the advantages of no radiation and high sensitivity is
why MRI, especially wbMRI, is now considered the gold
standard for disease monitoring in CNO, [12, 14, 17].
More than half of the patients in our study received a
wbMRI, suggesting the increasing recognition of this im-
aging tool in the appropriate management of CNO.
Consistent with current recommendation and practice,
the most common treatment reported prior to and after
CNO diagnosis was NSAIDs, [11, 18]. Antibiotic use
was the second most common treatment prior to the
final diagnosis, likely attributed to the difficulty in distin-
guishing infectious osteomyelitis from early noninfec-
tious osteomyelitis. In our study, about one-third of
patients received antibiotics prior to the diagnosis of
CNO. However, what was most surprising was that one
quarter used them for greater than 6 months. Prolonged
antibiotic treatment has not been proven to be beneficial
in patients with CNO, [3, 4, 19–21]. A consultation with
a pediatric rheumatologist in these cases may reduce the
Table 3 Self-reported Socioeconomic and Psychological Factors
Affected by CNO (n = 284)
Factors n (%)
Negative effect on:
Participation in extracurricular activities 174 (61)
Patient’s school/work attendance 151 (53)
Patient’s school performance 132 (47)
Finances 101 (36)
Parent’s job attendance/performance 96 (34)
Relationship with peers 86 (30)
Relationship with parents 82 (29)
Parent’s ability to perform daily tasks 76 (27)
Relationship with siblings 71 (25)
Fatigue 143 (50)
Problems with sleep 106 (37)
Anxiety 100 (35)
General feelings of unwell 99 (35)
Depression 91 (32)
Problems with anger management 54 (19)
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duration of ineffective antibiotic treatment and can help
make a timely diagnosis to begin effective interventions.
After the diagnosis of CNO, the reported use of antibi-
otics dramatically decreased. The use of medications
more appropriate for the treatment of CNO and consist-
ent with the current clinical practices of pediatric rheu-
matologists increased, specifically the use of DMARDs,
TNFi, bisphosphonates and steroids, [11, 12].
NSAIDs are typically the first choice for the initial treat-
ment and are an effective therapy for CNO, [3, 7, 14].
While the majority used NSAIDs after a diagnosis of
CNO, most patients did not find them to be the most
helpful therapy. An even lower number of patients on
DMARDs thought they were the most helpful medica-
tions, which are typically second line management. In-
stead, the most helpful therapies reported by patients and
families for CNO management were TNFi, followed by
bisphosphonates. Patients with multifocal disease or re-
currences usually require more intensive therapies, but
our study was not designed to differentiate disease severity
among the participants.
Socioeconomic and psychological stressors related to
CNO were major concerns for both the patient and the
parent. Both reported interference with school and work.
Overall performance and function were commonly chal-
lenged by pain, fatigue and physical limitation related to
CNO. Relationships with family and peers were nega-
tively affected. These findings are similar to the resulted
by Silier et al., [18], and demonstrate an unmet need for
psychosocial and socioeconomic support for the patients
and families of this chronic disease. Additional support
is needed for patients and their families to help cope
with socioeconomic stressors and mental health matters
and to establish school accommodations, such as a 504
plan, which is an education program in the United States
that addresses needed accommodations for children with
chronic disease to help prevent them from falling behind
academically.
Our study is not without limitations. We recognized a
possible sampling bias and participation bias with the on-
line survey format and invitations through social media to
collect data. However, we were able to reach a larger sam-
ple quickly, easily and on an international level through
these methods, which we could not have done otherwise
for this rare disease. This survey is the largest sampling of
international CNO patients and their families to date. The
data are self-reported and thus the accuracy of the infor-
mation might be affected, particularly with the questions
surrounding mental health. The majority of the survey
was filled out by the parents, which may not reflect the
psychosocial aspect of their children precisely. Treatment
responses were also self-reported, which lack verification.
While a majority had self-reported being diagnosed with
CNO by a pediatric rheumatologist, we were unable to
confirm the diagnosis by a health professional. Lastly, the
survey was not designed to prevent participants from tak-
ing the survey more than once and a single participant
could have filled out the survey multiple times.
Fig. 2 CNO Impact on Performance and Function
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Conclusions
Our results emphasize the importance of understanding
the challenges faced by patients and families with CNO
and the need for raising awareness for this rare disease
in order to improve patient care and reduce disease bur-
den. Patients with CNO experienced on average a 2-year
delay in diagnosis and receiving effective treatments. At
least 25% reported problems with relationships, school,
work, finances and well-being due to CNO. Our next
steps should focus on educating the medical community
about CNO to facilitate earlier referrals to rheumatolo-
gists for appropriate initial management, assistance with
obtaining MRI imaging, guidance on effective treatments
and additional support for socioeconomic stressors and
mental health matters.
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